Document:

Form of Change of Control Severance and Retention Agreement

 Exhibit 10.3 
 CHANGE IN CONTROL SEVERANCE AND RETENTION AGREEMENT 
 This CHANGE IN CONTROL SEVERANCE AND RETENTION
AGREEMENT (as modified, extended or supplemented from time to time, this “Agreement”) is entered into as of June 5, 2006 (the “Effective Date”) by and between Encore Capital Group, Inc., a Delaware corporation
(the “Company”), and ______________ (“Executive”). 
 1. Definitions. As used in this Agreement and
unless otherwise defined herein, capitalized terms will have the respective meanings set forth in Appendix A. 
 2. Term of Agreement.
This Agreement shall be effective on the date hereof and shall continue in effect until the first anniversary of the Effective Date if no Change in Control has occurred by that time, or until the end of the twelve month period following a Change in
Control, if a Change in Control has occurred prior to the first anniversary of the Effective Date. 
 3. Payments Upon Termination of
Employment. 
 (a) If during the Termination Period the employment of Executive shall terminate pursuant to a Qualifying
Termination, then the Company shall provide to Executive: 
 (1) Within ten (10) days following the Date of Termination a
lump-sum cash amount equal to the Executive’s base salary through the Date of Termination and any bonus amounts which have become payable, to the extent not previously paid or deferred; plus 
 (2) Subject to Section 3(c) below, a cash severance amount equal to one times Executive’s highest annual rate of base salary
during the 12-month period immediately prior to Executive’s Date of Termination, paid in equal installments over the one-year period commencing with the first regular payroll date following the Date of Termination in accordance with the
Company’s normal payroll practices; provided that, if necessary to avoid tax penalties under Section 409A of the Internal Revenue Code of 1986, as amended, the commencement of such payments shall be delayed until the first regular payroll
date which occurs more than six months following the Date of Termination, with the first of such payments including all payments which would have been made during the period of such delay without regard thereto, without interest. 
 (b) If during the Termination Period the employment of Executive shall terminate other than by reason of a Qualifying Termination, then
the Company shall pay to Executive within thirty (30) days following the Date of Termination, a lump-sum cash amount equal to Executive’s base salary through the Date of Termination and any bonus amounts which have become payable, to the
extent not previously paid or deferred. 
 (c) Executive acknowledges and agrees that any and all payments to which Executive
may become entitled under Section 3(a)(2) above are conditioned upon and 

 
subject to Executive’s execution of, and not having revoked within any applicable revocation period, a general release and waiver, in such reasonable
and customary form as shall be prepared by the Company, of all claims Executive may have against the Company and its directors, officers, subsidiaries and affiliates, except as to (i) matters covered by provisions of this Agreement that
expressly survive the termination of this Agreement, (ii) rights to indemnification and insurance under the Charter, By-Laws and directors and officers insurance policies maintained by the Company or any Subsidiary and (iii) rights to
which Executive is entitled by virtue of his participation in the employee benefit plans, policies and arrangements of the Company or any Subsidiary. 
 4. Retention Bonus. If Executive remains employed through the consummation of a Change in Control, he shall receive a lump sum payment of the Retention Bonus within ten (10) days following the consummation
of the Change in Control. 
 5. Withholding Taxes. The Company may withhold from all payments due to Executive (or his beneficiary or
estate) hereunder all taxes which, by applicable federal, state, local or other law, the Company is required to withhold therefrom. 
 6.
Scope of Agreement. Nothing in this Agreement shall be deemed to entitle Executive to continued employment with the Company or any Subsidiary, and if Executive’s employment shall terminate prior to a Change in Control, Executive shall
have no further rights under this Agreement other than as stated in Section 4; provided, however, that any termination of Executive’s employment during the Termination Period shall be subject to all of the provisions of this
Agreement. 
 7. Successors; Binding Agreement. 
 (a) This Agreement shall not be terminated by any reorganization, merger or consolidation involving the Company (each, a “Business
Combination”). In the event of any Business Combination, the provisions of this Agreement shall be binding upon the person resulting from such Business Combination (the “Surviving Person”), and the Surviving Person shall be
treated as the Company hereunder. 
 (b) This Agreement shall inure to the benefit of and be enforceable by Executive’s
personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Executive shall die while any amounts would be payable to Executive hereunder had Executive continued to live, all such amounts,
unless otherwise provided herein, shall be paid in accordance with the terms of this Agreement to such person or persons appointed in writing by Executive to receive such amounts or, if no person is so appointed, to Executive’s estate.

 8. Notice. For purposes of this Agreement all notices and other communications required or permitted hereunder shall be in writing
and shall be deemed to have been duly given (1) on the date of delivery if delivered personally or by facsimile upon confirmation of receipt, (2) on the first business day following the date of dispatch if delivered by a recognized
next-day courier service or (3) five days after deposit in the United States mail, 

 
certified and return receipt requested, postage prepaid. All such notices and communications shall be delivered as set forth below. 
 If to Executive, to the home address of Executive 
 last appearing in the Company’s records. 
 If to the Company: 
 Encore Capital Group, Inc. 
 8875 Aero Drive

 Suite 200 
 San Diego,
California 92123 
 Attn: General Counsel 
 with a copy addressed to the attention of the General Counsel of the Company at the above address, 
 or to such other address as either party may
have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt. 
 9. Full Settlement. In the event of a Qualifying Termination, the Company’s obligation to make any payments provided for in this Agreement and otherwise to perform its obligations hereunder shall be in lieu and in full
settlement of all other severance payments to Executive under any other severance or employment agreement between Executive and the Company. The Company’s obligations hereunder shall not be affected by any set-off, counterclaim, recoupment
defense or other claim, right or action which the Company may have against Executive or others. In no event shall Executive be obligated to seek other employment or take other action by way of mitigation of the amounts payable to Executive under any
of the provisions of this Agreement and such amounts shall not be reduced whether or not Executive obtains other employment. 
 10.
Employment with Subsidiaries. Employment with the Company for purposes of this Agreement shall include employment with any Subsidiary. 
 11. Restrictive Covenants. 
 (a) Cessation of Rights to Certain Future, Contingent Payments Upon Entering
Competitive Employment. If Executive, during the one (1) year period commencing on and following the Date of Termination (whether prior to or following a Change in Control), directly or indirectly, without the prior written consent of the
Board, becomes employed by, or acts as a consultant to or in association with, or as a director, officer, employee, partner, owner, joint venturer, member or otherwise, of any person, firm, corporation, partnership, limited liability company,
association or other entity that engages in any business in which the Company or any Subsidiary was engaged, or in which any of them had taken demonstrable steps to become engaged, at the Date of Termination, in the same geographical area in which
any of them engage, or are planning on becoming engaged, in such business (other than by beneficial ownership of up to 2% of the outstanding voting stock of a publicly-traded company that is or owns such a competitor), Executive’s right to
receive severance payments then being made by the Company pursuant to Section 3(a)(2) shall immediately cease and the Company’s obligation to make such 

 
payments under Section 3(a)(2) shall immediately terminate as of the date Executive enters into such employment or other relationships as described in
this Section 11(a). 
 (b) Non-Solicitation. Executive agrees that for one (1) year commencing on and
following the Date of Termination (whether prior to or following a Change in Control), Executive will not directly or indirectly (i) solicit or hire or encourage the solicitation or hiring of any person who was an employee of the Company or any
Subsidiary at any time on or after the Date of Termination (unless more than six (6) months shall have elapsed between the last day of such person’s employment by the Company and any Subsidiary and the first date of such solicitation or
hiring) or (ii) induce or attempt to induce any employee of the Company or any Subsidiary to leave the employ thereof or in any way interfere with the relationship between the Company or any Subsidiary and any employee thereof. 
 (c) Non-Disclosure of Confidential Information. Executive recognizes that the services Executive performs for the Company and its
affiliates are special, unique and extraordinary in that Executive may acquire confidential information, trade secrets or other competitive information concerning the operations of the Company and its affiliates, the use or disclosure of which could
cause the Company and its affiliates substantial loss and damages which could not be readily calculated, and for which no remedy at law would be adequate. Accordingly, Executive agrees that Executive will not at any time during Executive’s
employment with the Company or any Subsidiary or thereafter, except in performance of Executive’s obligations thereto, disclose, either directly or indirectly, any Confidential Information (as hereinafter defined) that Executive may learn by
reason of his association with the Company and its affiliates. The term “Confidential Information” shall mean any past, present or future confidential or secret plans, programs, documents, agreements, internal management reports,
financial information or other material relating to the business, strategies, services or activities of the Company and its affiliates, including, without limitation, information with respect to the Company’s and its affiliates’
operations, processes, products, inventions, business practices, finances, principals, vendors, suppliers, customers, potential customers, marketing methods, costs, prices, contractual relationships (including leases), regulatory status,
compensation paid to employees or other terms of employment, and trade secrets, market reports, customer investigations, customer lists and other similar information that is proprietary information of the Company or any of its affiliates.
Notwithstanding the foregoing, Executive may disclose such Confidential Information when required to do so by a court of competent jurisdiction, by any governmental agency having supervisory authority over the business of the Company and/or its
affiliates, as the case may be, or by any administrative body or legislative body (including a committee thereof) with jurisdiction to order Executive to divulge, disclose or make accessible such information; provided, further, that in the event
that Executive is ordered by any such court or other government agency, administrative body or legislative body to disclose any Confidential Information, Executive shall (i) promptly notify the Company of such order, (ii) at the written
request of the Company, diligently contest such order at the sole expense of the Company as expenses occur and (iii) at the written request of the Company, seek to obtain, at the sole expense of the Company, such confidential treatment as may
be available under applicable laws for any information disclosed under such order. 
 (d) Non-disparagement. The
Executive agrees (whether during or after the Executive’s employment with the Company) not to issue, circulate, publish or utter any 

 
false or disparaging statements, remarks or rumors about the Company or the officers or directors of the Company other than to the extent reasonably
necessary in order to (i) assert a bona fide claim against the Company arising out of the Executive’s employment with the Company, or (ii) respond in a truthful and appropriate manner to any legal process or give truthful and
appropriate testimony in a legal or regulatory proceeding. 
 (e) Mutual Dependence of Covenants and Condition
Subsequent. Executive covenants and agrees to be bound by the restrictive covenants and agreements contained in this Section 11 to the maximum extent permitted by Delaware law, it being the intent and spirit of the parties that the
restrictive covenants and agreements contained in this Agreement shall be valid and enforceable in all respects, and, subject to the terms and conditions of this Agreement, Executive’s compliance with the covenants contained in
Section 11(a) is mutually dependent upon and a condition subsequent to the Company’s obligation to make the payments described in Section 3(a)(2) of this Agreement and such payments shall immediately cease upon any breach of
Section 11(a). Likewise, if Executive commences any action in court or in arbitration challenging the validity of, seeking to invalidate or otherwise seeking some sort of declaration that the covenants and agreements in Section 11(a) are
void, voidable or invalid, the Company’s obligations to make the payments described in Section 3(a)(2) of this Agreement shall immediately cease as of the time of the commencement of such action or proceeding. If the Company does not
discover Executive’s breach of Section 11(a) or the commencement of any such action or arbitration proceedings until after one or more payments under Section 3(a)(2) have been made to Executive, Executive shall be obligated to
immediately return all such payments to the Company that were paid and received after the breach of Section 11(a). 
 (f)
Remedies Upon Breach. If the Executive breaches the provisions of Sections 11(b), (c) or (d), the Company shall have the right to have such restrictive covenants specifically enforced by any court of competent jurisdiction, it being
agreed that any breach of such restrictive covenants would cause irreparable injury to the Company and that money damages would not provide an adequate remedy for such injury. Accordingly, the Company shall be entitled to injunctive relief to
enforce the terms of such restrictive covenants and to restrain the Executive from any violation thereof. The rights and remedies set forth in this Section 11(f) shall be independent of all other others rights and remedies available to the
Company for a breach of such restrictive covenants, and shall be severally enforceable from, in addition to, and not in lieu of, any other rights and remedies available at law or in equity. 
 12. Survival. The respective obligations and benefits afforded to the Company and Executive as provided in Sections 3 (to the extent that payments
or benefits are owed as a result of a termination of employment that occurs during the term of this Agreement), 5, 7(b), 9 and 11 shall survive the termination of this Agreement. 
 13. Dispute Resolution. The Company and Executive agree that any controversy or claim arising out of or relating to this Agreement (other than a
controversy under Section 11 of this Agreement), or the breach thereof, shall be settled by arbitration administered by the American Arbitration Association in accordance with its Employment Arbitration Rules then in effect. Venue for any
arbitration pursuant to this Agreement will lie in San Diego, California. One of the arbitrators shall be appointed by the Company, one shall be appointed by Executive and the third shall be appointed by the first two arbitrators. If the first two
arbitrators 

 
cannot agree on the third arbitrator within 30 days following the appointment of the second arbitrator, then the third arbitrator shall be appointed by the
Association. All three arbitrators shall be experienced in the resolution of disputes under employment agreements for senior executives of major corporations. Any award entered by the arbitrators shall be final, binding and nonappealable and
judgment may be entered thereon by either party in accordance with applicable law in any court of competent jurisdiction. This arbitration provision shall be specifically enforceable. The arbitrators shall have no authority to modify any provision
of this Agreement or to award a remedy for a dispute involving this Agreement other than a benefit specifically provided under or by virtue of the Agreement. Each party shall be responsible for its own expenses relating to the conduct of the
arbitration (including reasonable attorneys’ fees and expenses). The Company shall pay the fees of the American Arbitration Association and the arbitrators, if applicable. 
 14. GOVERNING LAW; CONSENT TO JURISDICTION. THIS AGREEMENT WILL BE GOVERNED BY, AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF
DELAWARE APPLICABLE TO AGREEMENTS MADE AND TO BE WHOLLY PERFORMED WITHIN THAT STATE, WITHOUT REGARD TO THE CONFLICT OF LAWS PROVISIONS OF ANY JURISDICTION WHICH WOULD CAUSE THE APPLICATION OF ANY LAW OTHER THAN THAT OF THE STATE OF DELAWARE. ANY
ACTION TO ENFORCE THIS AGREEMENT (OTHER THAN AN ACTION WHICH MUST BE BROUGHT BY ARBITRATION PURSUANT TO SECTION 13) MUST BE BROUGHT IN, AND THE PARTIES HEREBY CONSENT TO THE JURISDICTION OF, A COURT SITUATED IN NEW YORK, NEW YORK. EACH PARTY HEREBY
WAIVES THE RIGHTS TO CLAIM THAT ANY SUCH COURT IS AN INCONVENIENT FORUM FOR THE RESOLUTION OF ANY SUCH ACTION. 
 15. JURY TRIAL
WAIVER. THE PARTIES EXPRESSLY AND KNOWINGLY WAIVE ANY RIGHT TO A JURY TRIAL IN THE EVENT ANY ACTION ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT IS LITIGATED OR HEARD IN ANY COURT. 
 16. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which together shall
constitute one, and the same instrument. 
 17. Miscellaneous. No provision of this Agreement may be modified or waived unless such
modification or waiver is agreed to in writing and signed by Executive and by a duly authorized officer of the Company. No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or
provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time. Failure by Executive or the Company to insist upon strict
compliance with any provision of this Agreement or to assert any right Executive or the Company may have hereunder shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement. Except as otherwise
specifically provided herein, the rights of, and benefits payable to, Executive, his estate or his beneficiaries pursuant to this Agreement are in addition to any rights of, or benefits payable to, 

 
Executive, his estate or his beneficiaries under any other employee benefit plan or compensation program of the Company. 
 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by a duly authorized officer of the Company and Executive has executed this
Agreement as of the day and year first above written. 
  

					
	ENCORE CAPITAL GROUP, INC.
		
	By:	 	/s/ Brandon Black
		 	Name:	 	Brandon Black
		 	Title:	 	Chief Executive Officer
	
	  
	[NAME OF EXECUTIVE]

 Appendix A 
 (Certain Defined Terms) 
 As used in the Agreement the following terms shall have the respective
meanings set forth below: 
 1. “Board” means the Board of Directors of the Company. 
 2. “Cause” means (a) any failure to adhere to any written policy of the Company that is legal and generally applicable to employees
of the Company; (b) failure by the Executive to substantially perform his duties, which failure amounts to a repeated and consistent neglect of his duties; (c) the appropriation (or attempted appropriation) of a material business
opportunity of the Company or any subsidiary thereof, including attempting to secure or securing any personal profit in connection with any transaction entered into on behalf of the Company or any subsidiary thereof; (d) the misappropriation
(or attempted misappropriation) of any of the Company’s funds or property; (e) the conviction of, or the entering of a guilty plea or plea of no contest, with respect to a felony, the equivalent thereof, a crime of moral turpitude or any
other crime with respect to which imprisonment is a possible punishment; (f) conduct materially injurious to the Company’s reputation or business; or (g) willful misconduct. 
 3. “Change in Control” means the occurrence of any one of the following events: 
 (a) the Company is merged into or consolidated with another corporation, in a transaction in which, upon completion, the Company’s
stockholders beneficially own (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), less than 50% of the total voting securities entitled to vote generally in the election of
directors of the surviving or resulting company outstanding; 
 (b) all or substantially all of the assets of the Company are
acquired by another corporation or business entity; 
 (c) any person (as such term is used in Section 13(d) and 14(d)(2)
of the Exchange Act), other than an employee benefit plan of the Company or any subsidiary of the Company or any entity holding shares of capital stock of the Company for or pursuant to the terms of any such employee benefit plan in its role as an
agent or trustee for such plan, shall acquire 50% or more of the Company’s outstanding voting stock entitled to vote generally in the election of directors; or 
 (d) a majority of the directors of the Company being individuals not nominated by the Board. 
 Notwithstanding the foregoing, the events described above shall not be deemed to be a Change in Control if they occur as a result of (i) a
transaction involving 

 
any person (as defined in clause 3(c)) which is the beneficial owner (as defined in clause 3(a)) as of the date of this Agreement, of more than 5% of the
Company’s outstanding voting stock entitled to vote generally in the election of directors or any associate or affiliate of such person (as such terms are defined in Rule 405 promulgated under the Securities Act of 1933, as amended) or
(ii) in the case of clause 3(c), a person acquiring such 50% ownership position as a result of the acquisition by the Company of its voting stock which reduces the number of outstanding shares of voting stock of the Company. 
 4. “Compensation Committee” means the Compensation Committee of the Board. 
 5. “Date of Termination” means (a) the effective date on which Executive’s employment by the Company or any Subsidiary
terminates as specified in a prior written notice by the Company, such Subsidiary or Executive, as the case may be, to the other, delivered pursuant to Section 8 or (b) if Executive’s employment by the Company or any Subsidiary
terminates by reason of death, the date of death of Executive. 
 6. “Disability” means termination of Executive’s
employment by the Company or any Subsidiary due to Executive’s absence from Executive’s duties on a full-time basis for at least one hundred eighty (180) consecutive days as a result of Executive’s incapacity due to physical or
mental illness. 
 7. “Good Reason” means, without Executive’s express written consent, the occurrence of any of the
following events after a Change in Control: 
 (a) a significant and material reduction in the Executive’s duties,
responsibilities and authority; 
 (b) any reduction in base salary; or 
 (c) any relocation by the Company of the Executive’s employment to a location outside of Southern California without the
Executive’s consent. 
 8. “Qualifying Termination” means a termination of Executive’s employment (a) by the
Company or any Subsidiary other than for Cause or (b) by Executive for Good Reason. Termination of Executive’s employment on account of death or Disability shall not be treated as a Qualifying Termination. 
 9. “Retention Bonus” means ___% of Executive’s highest annual rate of base salary during the period commencing one year prior to a
Change in Control and ending on date of payment of the Retention Bonus pursuant to Section 4 of the Agreement. 
 10.
“Subsidiary” means any corporation or other entity in which the Company has a direct or indirect ownership interest of 50% or more of the total combined voting power of the then outstanding securities or interests of such
corporation or other entity entitled to vote generally in the election of directors or in which the 

 
Company has the right to receive 50% or more of the distribution of profits or 50% of the assets on liquidation or dissolution. 
 11. “Termination Period” means the period of time beginning with a Change in Control and ending twelve months following such Change in
Control.Amendment No. 1 and Consent

 Exhibit 10.1 
 AMENDMENT NO. 1 AND CONSENT 
 THIS AMENDMENT NO. 1 AND CONSENT, dated as of June 6, 2006 (this
“Amendment”), of that certain Credit Agreement referenced below is by and among MILLIPORE CORPORATION, a Massachusetts corporation (the “Company” or the “Domestic Borrower”) and the other Borrowers,
Guarantors and Lenders identified on the signature pages hereto and BANK OF AMERICA, N.A., as Administrative Agent for and on behalf of the Lenders. Capitalized terms used but not otherwise defined herein shall have the meanings provided in the
Credit Agreement. 
 W I T N E S S E T H 
 WHEREAS, a €430 million revolving credit facility has been established in favor of the Company and certain of its subsidiaries pursuant to the terms
of that certain Credit Agreement dated as of December 15, 2005 (as amended, restated, increased, supplemented or otherwise modified from time to time, the “Credit Agreement”) among (i) the Company, as domestic borrower,
(ii) Millipore Ireland B.V., a limited liability company existing under the laws of the Netherlands, Millipore Cork, an unlimited company existing under the laws of Ireland, Millipore SAS, a limited liability company existing under the laws of
France, as foreign borrowers, (iii) the Company and certain of its subsidiaries, as guarantors, (iv) the lenders identified therein, and (v) Bank of America, N.A., as administrative agent; 
 WHEREAS, the Company intends to acquire (the “Acquisition”), by way of merger (the “Merger”), one hundred percent
(100%) of the capital stock of Serologicals Corporation, a Delaware corporation (the “Subject Company”), pursuant to the terms of that Agreement and Plan of Merger dated as of April 25, 2006 (as amended and modified, the
“Merger Agreement”) among the Company, Charleston Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company, and the Subject Company; 
 WHEREAS, consideration for the Acquisition, including cash-out of all equity-based awards and assumption of convertible debentures and existing
indebtedness, will be approximately US$1.47 billion; 
 WHEREAS, in order to finance the Acquisition, the Company intends to consider, among
other things, the issuance of indebtedness in the capital markets in the form of unsecured convertible notes (the “MIL Convertible Notes”) or other debt securities (the “Additional Notes” and, together with the MIL
Convertible Notes, the “Serologicals Acquisition Debt”); 
 WHEREAS, the Company has requested consent to certain amendments
of the Credit Agreement to permit the Acquisition and the Serologicals Acquisition Debt and to make certain other modifications to the Credit Agreement; 
 WHEREAS, the Lenders have agreed to the requested consent and modifications on the terms and conditions set forth herein and have directed the Administrative Agent to enter into this Amendment on their behalf;

 NOW, THEREFORE, in consideration of these premises and other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the parties agree as follows: 
 1. Consent. Notwithstanding provisions to the contrary in the Credit Agreement,
consent is hereby given for the exclusion of the effects of the Serologicals Acquisition Debt from the financial covenants in Section 8.02 of the Credit Agreement until the earlier of (a) consummation of the Acquisition or
(b) September 30, 2006. 

 2. Amendments to Credit Agreement Effective Prior to Consummation of Acquisition. Subject to the
terms and conditions set forth herein, the Credit Agreement is amended in the following respects: 
 2.1. In Section 1.01 (Definitions),
the following definitions are amended and restated in their entirety or added, as appropriate, to read as follows: 
 “Additional Notes” has the meaning provided in Section 8.01(j). 
 “Consolidated
Interest Expense” means, for any period for the Consolidated Group, all interest expense, including the amortization of debt discount and premium, the interest component under capital leases and the implied interest component under
Securitization Transactions, in each case on a consolidated basis determined in accordance with GAAP but excluding, for purposes hereof, interest expense attributable to the Serologicals Acquisition Debt until the earlier of
(a) consummation of the Permitted Serologicals Acquisition, or (b) September 30, 2006. Except as otherwise expressly provided, the applicable period shall be the four consecutive fiscal quarters ending as of the date of determination.

 “Consolidated Total Funded Debt” means Funded Debt of the Consolidated Group determined on a consolidated
basis in accordance with GAAP; but excluding, for purposes hereof, the Serologicals Acquisition Debt until the earlier of (a) consummation of the Permitted Serologicals Acquisition, or (b) September 30, 2006. 
 “Merger Agreement” has the meaning provided in the definition of Permitted Serologicals Acquisition. 
 “MIL Convertible Notes” has the meaning provided in Section 8.01(j). 
 “Permitted Serologicals Acquisition” means the acquisition, by merger or otherwise, of one hundred percent (100%) of
the Capital Stock of Serologicals pursuant to the terms of that certain Agreement and Plan of Merger (the “Merger Agreement”) dated as of April 25, 2006, as amended, modified and supplemented, by and among the Company,
Charleston Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company, and Serologicals; provided that (a) material amendments, modifications and supplements to the Merger Agreement that are adverse to the
Lenders shall be reasonably acceptable to the Administrative Agent and the Lenders, and (b) total purchase consideration therefor (including cash-out of equity-based awards and assumed convertible debentures and indebtedness) is not more than
US$1.5 billion. 
 “Senior Parity Debt” has the meaning provided in the definition of Permitted Liens.

 “Serologicals” means Serologicals Corporation, a Delaware corporation. 
 “Serologicals Acquisition Debt” has the meaning provided in Section 8.01(j). 
 2.2 In Section 1.01 (Definitions), the following definitions are amended as follows: 
 (a) In the definition of “Permitted Acquisition” there shall be inserted immediately prior to the lead-in clause that reads
“any Acquisition of a controlling interest in another Person by a member of the Consolidated Group that satisfies the following conditions” the text “(i) the Permitted Serologicals Acquisition and (ii)”. 
  

 2 

 (b) In the definition of “Permitted Liens”, clauses (b) through
(q) shall be relabeled as (c) through (r), respectively, and a new clause (b) shall be added to read as follows: 
 (b) Liens to secure other senior parity indebtedness of the Company permitted hereunder (not including subordinated indebtedness or indebtedness convertible into subordinated indebtedness or equity interests) (“Senior Parity
Debt”); provided that (i) such Liens are on some or all of the same collateral that secures the Loans and obligations hereunder, (ii) the loans and obligations under the Senior Parity Debt and the Loans and obligations
hereunder shall share pari passu in the collateral that is subject to such Liens, and (iii) an intercreditor agreement shall have been executed in respect of the collateral, or the collateral documents shall otherwise include
intercreditor provisions, reasonably acceptable to the Administrative Agent and the Required Lenders; 
 2.3 In Section 6.02 (No
Material Adverse Effect), the text “the date of the most recent annual audited financial statements referenced in Section 6.01(a)” is deleted and replaced with the text “December 31, 2005”. 
 2.4 In Section 7.11 (Guarantors), a new subsection (c) is added to read as follows: 
 (c) In addition, the Company will cause any member of the Consolidated Group that guarantees the Serologicals Acquisition Debt to promptly
join as a Guarantor hereunder in accordance with the joinder provisions of subsection (a) or (b) above, as appropriate. 
 2.5 In Section 8.01 (Indebtedness), the word “and” at the end of subsection (i) is deleted, subsection (j) is relabeled as (k) and a new subsection (j) is added to read as follows: 
 (j) Indebtedness of the Company to finance the Permitted Serologicals Acquisition, including indebtedness in the form of unsecured
convertible notes (the “MIL Convertible Notes”) or other debt securities (the “Additional Notes”) and renewals, refinancings and extensions thereof without any increase in the principal amount being so renewed,
refinanced or extended (plus accrued and unpaid interest thereon), and guaranties thereof by other members of the Consolidated Group (together, the “Serologicals Acquisition Debt”); and 
 2.6 In Section 8.08 (Restricted Payments), the word “and” at the end of subsection (c) is deleted, subsection (d) is relabeled
as subsection (e) and a new subsection (d) is added to read as follows: 
 (d) so long as no Default or Event of
Default (other than Defaults or Events of Default described in Section 9.01(l)) shall exist immediately before or immediately after giving effect thereto, the Company may make payments (whether in cash, securities or other property) for
or on account of the purchase, redemption, retirement, acquisition, cancellation or termination of the Serologicals Acquisition Debt; and 
 2.7 In Section 8.11 (Limitation on Restricted Actions), the word “and” immediately following the text “and the other Credit Documents” is deleted and replaced with “,” and “and (iii) the
Serologicals Acquisition Debt” is inserted immediately before the period at the end of such Section. 
 2.8 Schedules 6.14 and 7.06 to
the Credit Agreement are amended and restated in their entirety to read as Schedules 6.14 and 7.06 attached hereto, respectively. 
  

 3 

 3. Amendments to Credit Agreement Effective Upon Consummation of Acquisition. Subject to the terms
and conditions set forth herein, the Credit Agreement is amended in the following respects: 
 3.1. In Section 1.01 (Definitions), the
following definitions are amended and restated in their entirety or added, as appropriate, to read as follows: 
 “Applicable Percentage” means, for any day, the rate per annum set forth below opposite the applicable Debt Rating, it being understood that the Applicable Percentage for (a) Base Rate Loans shall be the percentage set
forth under the column entitled “Applicable Percentage for Base Rate Loans”, (b) Eurocurrency Rate Loans shall be the percentage set forth under the column entitled “Applicable Percentage for Eurocurrency Rate Loans (Domestic
Revolving Loans and Foreign Revolving Loans) and Domestic Letter of Credit Fees”, (c) Domestic Letter of Credit Fees shall be the percentage set forth under the column entitled “Applicable Percentage for Eurocurrency Rate Loans
(Domestic Revolving Loans and Foreign Revolving Loans) and Domestic Letter of Credit Fees” and (d) the Commitment Fee shall be the percentage set forth under the column entitled “Commitment Fee”: 
  

									
	Pricing
Level	  	 Debt Rating
	  	Applicable Percentage
for Eurocurrency
Rate Loans (Domestic
Revolving Loans and
Foreign Revolving
Loans) and
Domestic
Letter of Credit Fees	 	Applicable
Percentage
for Base
Rate Loans	 	Commitment
Fee
	I	  	Better than BBB+ and Baa1	  	0.225%	 	0%	 	0.0675%
	II	  	BBB+ and Baa1	  	0.275%	 	0%	 	0.0825%
	III	  	BBB and Baa2	  	0.350%	 	0%	 	0.1050%
	IV	  	BBB- and Baa3	  	0.450%	 	0%	 	0.1350%
	V	  	BB+ and Ba1	  	0.600%	 	0%	 	0.1800%
	VI	  	BB and Ba2	  	0.850%	 	0%	 	0.2550%
	VII	  	BB- and Ba3 or worse	  	1.500%	 	0%	 	0.6000%

 The numerical classification set forth under the column “Pricing Level”
shall be established based on the Debt Rating by S&P and Moody’s (collectively, the “Rating Services”); provided that 
 (i) in the case of a split rating, (A) where the assigned Debt Rating is BBB- or better by S&P and Baa3 or better by Moody’s (an “Investment Grade Rating”), then the applicable pricing
level shall be determined by reference to the better of the ratings, and (B) where the assigned Debt Rating is not an Investment Grade Rating, then the “Applicable Percentage” shall be determined based on an average of the
corresponding pricing levels therefor; 
 (ii) if either Rating Service ceases to assign a Debt Rating for the Loans and
credit facilities under this Credit Agreement, the applicable pricing level shall be determined by reference to the Debt Rating for the Loans and credit facilities under this Credit Agreement assigned by the remaining Rating Service; and 

(iii) if both Rating Services cease to assign a Debt Rating for the Loans and credit facilities under this Credit Agreement, the
applicable pricing level shall be based on the Company’s issuer rating as determined by the Ratings Services, and if no issuer rating is available, then the applicable pricing level shall be determined by reference to the worst rating (Pricing
Level VII) shown in the pricing grid. 
  

 4 

 Any change in the applicable pricing level shall be effective from the date of change in
the Debt Rating and shall be effective as to all Loans and Credit Extensions, existing and prospective, from the date of such change. The Company shall notify the Administrative Agent of any change in the Debt Rating by either of the Ratings
Services within five (5) Business Days of such change. 
 “Consolidated EBITDA” means, for any period
for the Consolidated Group, the sum of (a) Consolidated Net Income plus (b) to the extent deducted in determining net income, (i) Consolidated Interest Expense, (ii) taxes, (iii) depreciation and amortization, in each
case on a consolidated basis determined in accordance with GAAP and (iv) non-recurring charges relating to the Permitted Serologicals Acquisition in an aggregate amount not to exceed US$50 million (the “Serologicals Restructuring
Charges”); provided that, for purposes hereof, Consolidated EBITDA shall exclude (w) all non-cash non-recurring charges otherwise deducted (other than non-cash charges arising from the write-off of current assets, but including
as a deduction to Consolidated EBITDA all subsequent cash expenditures made in the applicable period relating to non-cash non-recurring charges taken in a prior period) not in excess of ten percent (10%) of Consolidated EBITDA as of the end of
the most recent fiscal quarter (excluding previous adjustments), (x) acquired in-process research and development expense, (y) all non-cash non-recurring charges for the expense of equity based compensation under GAAP and (z) charges
relating to the step up in basis of acquired inventories. Except as otherwise expressly provided, the applicable period shall be the four consecutive fiscal quarters ending as of the date of determination. 
 “Consolidated Total Leverage Ratio” means, as of the last day of each fiscal quarter, the ratio of (a) Consolidated
Total Funded Debt on such day minus domestic cash on hand and Cash Equivalents of the Consolidated Group on such day in an amount not to exceed US$50 million to (b) Consolidated EBITDA for the period of four consecutive fiscal quarters ending
as of such day; provided that for purposes of calculating the Consolidated Total Leverage Ratio, Consolidated Total Funded Debt shall be deemed not to include the market value of the Serologicals Debentures to the extent of cash segregated
for the redemption or repayment of the Serologicals Debentures (without duplication for cash and Cash Equivalents used as an off-set to Consolidated Total Funded Debt under clause (a) immediately above). 
 “Debt Rating” means ratings issued by the Ratings Services for the Loans and credit facilities under this Credit
Agreement, or if no such rating is published, the issuer rating for the Company. 
 “Excluded Personal
Property” means (a) in the case of personal property located in the United States, any personal property in respect of which perfection of a Lien is not either (i) governed by the UCC (such as motor vehicles) or (ii) effected
by the filing of a notice of lien in respect of intellectual property with the United States Copyright Office or the United States Patent and Trademark Office, (b) any property that is the subject of Securitization Transaction permitted
hereunder or any related property that is subject to the agreements relating thereto, (c) any property that is the subject of a Lien permitted under clause (h) of the definition of “Permitted Liens” (and any related
property), if and to the extent that a grant of a security interest therein as contemplated by this Credit Agreement is prohibited or would result in the right to terminate, accelerate the indebtedness secured thereby, but only to the extent that
any such provisions are not rendered ineffective under the UCC or other applicable Law, and (d) any 

  

 5 

 
permit, lease, license, contract or instrument, if and to the extent that a grant of a security interest therein as contemplated by this Credit Agreement or
under applicable Law, is prohibited or would result in the termination thereof or give the other parties thereto the right to terminate, accelerate or otherwise materially alter the Credit Party’s rights, titles and interests thereunder
(whether upon the giving of notice, the lapse of time or both), but only to the extent that any such provisions are not rendered ineffective under the UCC or other applicable Law. 
 “First-Tier Foreign Subsidiary” means a Foreign Subsidiary that is owned directly by the Company or a Domestic Subsidiary
of the Company. 
 “Material Foreign Subsidiary” means a wholly-owned Subsidiary that, on an unconsolidated
basis including its Subsidiaries, has at least US$30 million in assets or generates at least US$20 million of Consolidated EBITDA for the period of four consecutive fiscal quarters most recently ended. 
 “Permitted Investments” means Investments that are (a) cash and Cash Equivalents; (b) accounts receivable
created, acquired or made in the ordinary course of business and payable or dischargeable in accordance with customary trade terms; (c) Investments consisting of Capital Stock, obligations, securities or other Property received in settlement of
accounts receivable (created in the ordinary course of business) from bankrupt obligors; (d) Investments made prior to the Closing Date and set forth in Schedule 8.07; (e) to the extent not prohibited by applicable Law, advances or
loans to employees for moving, entertainment, travel and other similar expenses in the ordinary course of business not to exceed US$1 million in the aggregate at any time outstanding; (f) advances or loans to customers and suppliers in the
ordinary course of business; (g) Investments existing on the Closing Date, by members of the Consolidated Group in other members of the Consolidated Group, (h) Investments by members of the Consolidated Group in and to other members of the
Consolidated Group in an Approved Jurisdiction, (i) Investments by members of the Consolidated Group that are not located in an Approved Jurisdiction in and to other members of the Consolidated Group that are not located in an Approved
Jurisdiction, (j) Investments by members of the Consolidated Group that are located in an Approved Jurisdiction in and to members of the Consolidated Group that are not located in an Approved Jurisdiction in an aggregate principal amount not to
exceed US$130 million (on a cost or investment basis), (k) the Permitted Serologicals Acquisition and (l) other Investments; provided that when the Consolidated Total Leverage Ratio is greater than 2.5:1.0, then such other
Investments shall be limited to an amount equal to the sum of $325 million plus fifty percent (50%) of cumulative net income from the Closing Date on a quarter-by-quarter basis. For purposes hereof, amounts paid or otherwise invested in
connection with an Acquisition will be considered to be an “Investment” subject to the conditions and limitations set out herein. 
 “Revolving Termination Date” means June 6, 2011. 
 “Serologicals Debentures” means the 4.75% Convertible Senior Subordinated Debentures due 2033 issued by Serologicals and outstanding as of the date of the consummation of the Permitted Serologicals Acquisition and the
Indebtedness represented thereby. 
 “Serologicals Restructuring Charges” has the meaning provided in the
definition of Consolidated EBITDA. 
 3.2 In Section 1.01 (Definitions), the definition of “Permitted Liens” is amended by
deleting the word “and” at the end of subsection (p) thereof, relabeling subsection (q) thereof as (t), and inserting the following text immediately after subsection (p): 
  

 6 

 (r) Liens required to be granted in connection with the Additional Notes as a result of
the granting of Liens pursuant to Sections 7.13 and 7.14 of this Credit Agreement; 
 (s) Liens required to
be granted in connection with the Company’s unsecured note due 2007 as a result of the granting of Liens pursuant to Sections 7.13 and 7.14 of this Agreement; and 
 3.3 In Section 7.11 (Additional Guarantors), subsection (a) is amended such that the text “; provided, however, that, prior
to the date nine (9) months after the date on which the Permitted Serologicals Acquisition is consummated, none of Serologicals or any of its Subsidiaries shall be required to become a Guarantor (unless, at any time after the consummation of
the Permitted Serologicals Acquisition, such entity provides a guarantee of other Indebtedness of any Person (other than guarantees in existence prior to the consummation of the Permitted Serologicals Acquisition), in which event such entity
providing such guarantee also shall be required to become a Guarantor if such entity would, notwithstanding this proviso, be required to become a Guarantor hereunder)” is inserted immediately before the period at the end of such Section.

 3.4 In Article VII (Affirmative Covenants), new Sections 7.13 and 7.14 are added to read as follows: 
 7.13 Additional Pledged Collateral. If at any time the Debt Rating is BB or worse by S&P (or unrated) and Ba2 or worse by
Moody’s (or unrated), then the Company will promptly pledge and will cause the other Domestic Credit Parties to promptly pledge to the Collateral Agent the following: 
 (a) Domestic Subsidiaries. One hundred percent (100%) of the Capital Stock with ordinary voting power owned by such Domestic
Credit Party to secure the Obligations pursuant to pledge agreements or pledge joinder agreements reasonably satisfactory to the Administrative Agent and the Required Lenders, together with original certificates evidencing the pledged interests and
undated stock powers executed in blank, filings and other deliveries necessary or appropriate to perfect the security interests therein, and opinions of counsel relating thereto, in each case in scope, form and substance reasonably satisfactory to
the Administrative Agent, the Collateral Agent and the Required Lenders. 
 (b) First-Tier Foreign Subsidiaries.
Sixty-five percent (65%) of the Capital Stock with ordinary voting power in all First-Tier Foreign Subsidiaries owned by such Domestic Credit Party that are Material Foreign Subsidiaries to secure the Obligations pursuant to pledge agreements
or pledge joinder agreements reasonably satisfactory to the Administrative Agent and the Required Lenders, together with original certificates evidencing the pledged interests and undated stock powers executed in blank, filings and other deliveries
necessary or appropriate to perfect the security interests therein, and opinions of counsel relating thereto, in each case in scope, form and substance reasonably satisfactory to the Administrative Agent, the Collateral Agent and the Required
Lenders. 
 (c) Remainder of First-Tier Foreign Subsidiaries and Material Foreign Subsidiaries. The remaining
thirty-five percent (35%) of the Capital Stock with ordinary voting power in the First-Tier Foreign Subsidiaries pledged pursuant to subsection (b) above to secure the Obligations of the Foreign Credit Parties, together with one
hundred percent (100%) of the Capital Stock with ordinary voting power in the Material Foreign Subsidiaries owned by the Foreign Credit Parties, to secure the Obligations of the Foreign Credit Parties pursuant to pledge agreements or pledge
joinder agreements reasonably 

  

 7 

 
satisfactory to the Administrative Agent and the Required Lenders, together with original certificates evidencing the pledged interests and undated stock
powers executed in blank, filings and other deliveries necessary or appropriate to perfect the security interests therein, and opinions of counsel relating thereto, in each case in scope, form and substance reasonably satisfactory to the
Administrative Agent, the Collateral Agent and the Required Lenders. 
 The foregoing pledge and security interests in this Section shall
(a) be made only to the extent not prohibited by applicable law and (b) remain in force and effect until the Debt Rating is better than BB by S&P and Ba2 by Moody’s (or, (i) if one Ratings Service shall cease to be in the
business of rating corporate debt obligations, then until the remaining rating is better than the level specified for the rating from the remaining Ratings Service in this clause (b) and (ii) if both Ratings Services shall cease to
be in the business of rating corporate debt obligations, then until the Consolidated Total Leverage Ratio is less than or equal to 2.5:1.0), whereupon in any such case, the pledge and security interests shall be promptly released and any possessory
collateral held by the Collateral Agent promptly returned to the appropriate parties. 
 7.14 Additional Personal and Real
Property Collateral. If at any time the Debt Rating is BB- or worse by S&P (or unrated) and Ba3 or worse by Moody’s (or unrated), then the Company and the other Credit Parties will, subject to Section 1.10, promptly
grant security interests to secure the Obligations in the following: 
 (a) Domestic Personal Property. A security
interest in substantially all personal property (including all accounts, contract rights, deposit accounts, chattel paper, insurance proceeds, inventory, investments and financial assets, general intangibles, intellectual property, licenses,
machinery and equipment) of such Credit Party located in the United States and which may be perfected by filing financing statements under the UCC or by filing notices of security interests in respect of intellectual property with the United States
Copyright Office or the United States Patent and Trademark Office. The scope of the personal property covered by this subsection will not include Excluded Personal Property. In connection with any grant of security interest under this subsection,
the Credit Parties will deliver to the Collateral Agent within thirty (30) days (with extensions as deemed necessary by the Collateral Agent) (i) a security agreement in form and substance reasonably satisfactory to the Administrative
Agent and Collateral Agent, executed in multiple counterparts, (ii) notices of grant of security interest in respect of intellectual property with the United States Copyright Office or the United States Patent and Trademark Office reasonably
satisfactory to the Collateral Agent, executed in multiple counterparts, (iii) customary opinions of counsel, in form and substance reasonably satisfactory to the Administrative Agent and Collateral Agent, (iv) evidence of casualty
insurance (consistent with the requirements for insurance hereunder) on personal property showing the Collateral Agent as loss payee (if insurance is provided by a commercial insurer), and (v) such other filings and deliveries as may be
necessary or appropriate as determined by the Collateral Agent in its reasonable discretion. 
 (b) Domestic Real
Property. Mortgage, pledge and grant of security interest in all fee-owned real property of such Credit Party located in the United States with a fair market value in excess of US$5 million in any instance (or otherwise determined to be material
in the reasonable judgment of the Administrative Agent and the Collateral Agent). Further, the Administrative Agent and Collateral Agent, in consultation with the Company, shall do an analysis of the relative benefits associated with the prospective
mortgage lien and where, in their reasonable discretion, the Administrative Agent and the Collateral Agent shall make a determination, taking into account local mortgage 

  

 8 

 
recording tax issues, that the costs, circumstances and requirements under local law associated with the mortgage lien outweigh the relative benefits of the
mortgage lien, then, in any such case, the mortgage will not be required. In connection with the mortgage, pledge or grant of a security interest under this subsection, the Credit Parties will deliver to the Collateral Agent within sixty
(60) days (with extensions as deemed necessary by the Collateral Agent) (i) a mortgage, deed of trust, deed to secure debt or other similar instrument in form and substance reasonably satisfactory to the Collateral Agent, executed in
multiple counterparts, (ii) copies of recent ALTA surveys prepared by registered engineers or land surveyors for each mortgaged property, (iii) standard ALTA mortgagee policies insuring the priority of the mortgage instruments and copies
of recorded documentation relating to any exceptions, (iv) copies of environmental reports and other material, non-privileged environmental documentation relating to the mortgaged properties, in each case in form and substance reasonably
acceptable to the Collateral Agent, (v) evidence of casualty insurance (consistent with the requirements for insurance hereunder) on the real property improvements showing the Collateral Agent as loss payee (if insurance is provided by a
commercial issuer), and (vi) evidence of flood insurance on improvements on the mortgaged properties that are located in a flood hazard area, with such insurance identifying the Collateral Agent as sole loss payee. 
 (c) Foreign Personal Property. A security interest in all material personal property (including all accounts, contract rights,
deposit accounts, chattel paper, insurance proceeds, inventory, investments and financial assets, general intangibles, intellectual property, licenses, machinery and equipment) of such Credit Party located outside the United States with a fair
market value in excess of US$5 million in any instance (or otherwise determined to be material in the reasonable discretion of the Administrative Agent and the Collateral Agent). The scope of the security interests will contain
exceptions and qualifications reasonably acceptable to the Administrative Agent and Collateral Agent, and will not include Excluded Personal Property. Further, the Administrative Agent and Collateral Agent, in consultation with the Company, shall do
an analysis of the relative benefits associated with the prospective pledge and where, in their reasonable discretion, the Administrative Agent and Collateral Agent shall make a determination, taking into account local custom and practice, that the
costs, circumstances and requirements under local law associated with the pledge outweigh the relative benefits of the pledge, then, in any such case, the pledge will not be required. In connection with the a grant of security interests under this
subsection, the Credit Parties will deliver to the Collateral Agent within ninety (90) days (with extensions as deemed necessary by the Collateral Agent) (i) a security agreement in form and substance reasonably satisfactory to the
Collateral Agent, executed in multiple counterparts, (ii) filings and notices of grant of security interest in respect of such personal property as may be necessary or appropriate to perfect the subject interests and otherwise reasonably
satisfactory to the Collateral Agent, (iii) such opinions of counsel as the Administrative Agent and the Collateral Agent may deem necessary or appropriate, in form and substance reasonably satisfactory to the Administrative Agent and the
Collateral Agent, (iv) evidence of casualty insurance (consistent with the requirements for insurance hereunder) on personal property showing the Collateral Agent and loss payee (if insurance is provided by a commercial insurer), and
(v) such other deliveries as may be customary, necessary or appropriate in the subject jurisdiction as determined by the Collateral Agent in its reasonable discretion. 
 The foregoing mortgage and security interests in this Section shall (a) be made only to the extent not prohibited by applicable law and
(b) remain in force and effect until the Debt Rating is better than BB- by S&P and Ba3 by Moody’s (or, if one Ratings Service shall cease to be in the 

  

 9 

 
business of rating corporate debt obligations, then until the remaining rating is better than the level specified for the rating from the remaining Ratings
Service in this clause (b) and (ii) if both Ratings Services shall cease to be in the business of rating corporate debt obligations, then until the Consolidated Total Leverage Ratio is less than or equal to 3.5:1.0), whereupon in
any such case, the mortgage and security interests shall be promptly released and any possessory collateral held by the Collateral Agent promptly returned to the appropriate parties. 
 3.5 Section 8.01 (Indebtedness) is amended as follows: 
 (a) in subsection (b), (i) the text “Closing Date” is deleted and replaced with the text “first date on which any part of Amendment No. 1 and Consent to this Credit Agreement has become
effective” and (ii) the text “, as amended as of such date” is inserted after the text “set forth on Schedule 8.01”; 
 (b) in clause (i) of the proviso to subsection (c), (i) the text “US$100 million” is deleted and replaced with the text “US$130 million”, and (ii) the text “(plus accrued
interest and premium, if any)” is inserted immediately after the text “principal balance outstanding” in clause (iii); 
 (c) at the end of subsection (j), the “and” is deleted, subsection (k) is relabeled as (l) and a new subsection (k) is added to read as follows: 
 (k) the Serologicals Debentures; and 
 (d) in subsection (k) (relabeled as (l)), the text “US$100 million” is deleted and replaced with the text “US$130 million”; and 
 (e) a new paragraph is added at the end of the Section to read as follows: 
 Notwithstanding anything contained herein to the contrary, until such time as Serologicals shall become a Guarantor hereunder, neither
Serologicals nor its Subsidiaries shall incur any additional Funded Debt (other than (i) purchase money Indebtedness in the ordinary course of business under subsection (c) above, (ii) debt from the Company or its Subsidiaries
in an aggregate principal amount at any time outstanding not to exceed (A) the Serologicals Restructuring Changes less (B) Investments made pursuant to clause (i) of the last paragraph of Section 8.07 of this
Credit Agreement and (iii) intercompany Indebtedness owing by and among Serologicals and its Subsidiaries under subsection (e) above). 
 3.6 Section 8.02 (Financial Covenants) is amended and restated in its entirety to read as follows: 
 8.02 Financial Covenants. 
 (a) Consolidated Total Leverage Ratio. As of the
end of each fiscal quarter, the Consolidated Total Leverage Ratio shall be not greater than the ratio set forth below opposite such fiscal quarter: 
  

			
	 Fiscal Quarter Ending
	  	Maximum Consolidated
Total Leverage Ratio
	 June 30, 2006
	  	5.25:1.0
	 September 30, 2006
	  	5.00:1.0
	 December 31, 2006
	  	4.75:1.0
	 March 31, 2007
	  	4.50:1.0
	 June 30, 2007
	  	4.25:1.0
	 September 30, 2007
	  	3.75:1.0
	 December 31, 2007 and thereafter
	  	3.50:1.0

  

 10 

 (b) Consolidated Interest Coverage Ratio. As of the end of each fiscal quarter,
the Consolidated Interest Coverage Ratio shall be not less than 3.50:1.0. 
 3.7 In Section 8.05, (a) subsection (a) is
amended such that (i) the text “enter into any transaction of” is replaced by the text “consummate any” in each place in which it appears, (ii) the text “be a party to a transaction of” is replaced by
“consummate any” in each place in which it appears, (iii) the text “is a party to” is replaced by the text “consummates” in each place in which it appears and (iv) the text “enter into a transaction
of” is replaced by the text “consummate a” in each place in which it appears and (b) a new paragraph is added at the end of such Section to read as follows: 
 Notwithstanding anything contained herein to the contrary, until such time as Serologicals shall become a Guarantor hereunder, neither
Serologicals nor its Subsidiaries will enter into or consummate a merger or consolidation except with a member of the Consolidated Group or make any Acquisition whether or not otherwise constituting a Permitted Acquisition hereunder. 
 3.8 In Section 8.06 (Asset Dispositions), a new paragraph is added at the end of such Section to read as follows: 
 Any calculation made pursuant to this Section 8.06 for the fiscal year ending December 31, 2006, shall be made on a pro forma basis taking into
account the Permitted Serologicals Acquisition. 
 3.9 In Section 8.07 (Investments), a new paragraph is added at the end of such
Section to read as follows: 
 Notwithstanding anything contained herein to the contrary, until such time as Serologicals
shall become a Guarantor hereunder, (x) members of the Consolidated Group (other than Serologicals and its Subsidiaries) will not make additional Investments in Serologicals and its Subsidiaries other than Investments in an amount not to exceed
(i) the Serologicals Restructuring Charges less (ii) the amount of Indebtedness incurred pursuant to clause (ii) of the last paragraph of Section 8.01 of this Credit Agreement, and (y) Serologicals and
its Subsidiaries will not make Investments in Persons outside the Consolidated Group. 
 3.10 In subsection (d) of Section 8.08
(Restricted Payments), the text “or the Serologicals Debentures” is inserted immediately after the text “the Serologicals Acquisition Debt”. 
 3.11 In Section 8.11 (Limitation on Restricted Actions), the text “and” immediately following the text “the subject of such financing” is deleted and replaced with the text “,” and
the text “and (iv) the Serologicals Debentures” is inserted immediately before the period at the end of such Section. 
  

 11 

 4. Conditions Precedent. 
 4.1 Conditions to Effectiveness of Sections 1 and 2. Sections 1 and 2 of this Amendment shall become effective upon the satisfaction of the
following conditions, in form and substance reasonably satisfactory to the Administrative Agent: 
 (a) receipt by the
Administrative Agent of executed copies of the consent and direction to this Amendment from the Required Lenders; and 
 (b)
receipt by the Administrative Agent of executed copies of the signature pages to this Amendment from the Company and the other Credit Parties. 
 The
Administrative Agent will notify the Company and the Lenders when the conditions to the effectiveness of the consents in Section 1 and the amendment provisions of Section 2 of this Amendment have been met and will confirm
that those provisions are effective. The provisions of Sections 1 and 2 shall not be effective until the Administrative Agent shall have given such confirmation. 
 4.2 Conditions to Effectiveness of Section 3. Section 3 of this Amendment shall become effective upon the satisfaction of the following
conditions, in form and substance reasonably satisfactory to the Administrative Agent: 
 (a) receipt by the Administrative
Agent of executed copies of the consent and direction to this Amendment from the Required Lenders, provided that the amended definition of “Revolving Termination Date” set forth in Section 3.1 of this Amendment shall become effective
only upon receipt by the Administrative Agent of executed copies of the consent and direction to this Amendment from all the Lenders; 
 (b) receipt by the Administrative Agent of executed copies of the signature pages to this Amendment from the Company and the other Credit Parties; 
 (c) receipt of corporate resolutions, incumbency certificates, supporting corporate formation and organizational documentation and
opinions of counsel reasonably satisfactory to the Administrative Agent; 
 (d) commercially reasonable efforts having been
made to obtain Debt Ratings for the Loans and credit facilities under the Credit Agreement; 
 (e) evidence that the
Acquisition has been consummated substantially in accordance with the terms of the Merger Agreement, with such amendments, modifications, supplements and waivers copies of which shall have been given to, and which are reasonably acceptable to, the
Administrative Agent and the Lenders, it being understood that a copy of the Certificate of Merger certified by the Secretary of the State of Delaware shall be deemed sufficient evidence that the Acquisition has been consummated; and 
 (f) payment of all fees and expenses (including fees and expenses of counsel to the Administrative Agent) in connection with this
Amendment. 
 The Administrative Agent will notify the Company and the Lenders when the conditions to the effectiveness of the amendment provisions of
Section 3 of this Amendment have been met and will confirm that those provisions are effective. The provisions of Section 3 shall not be effective until the Administrative Agent shall have given such confirmation. 

 

 12 

 5. Representations and Warranties; Defaults. The Credit Parties affirm the following: 

(a) all necessary action to authorize the execution, delivery and performance of this Amendment has been taken; 
 (b) after giving effect to this Amendment, the representations and warranties set forth in the Credit Agreement and the other Credit
Documents are true and correct in all material respects as of the date hereof (except those which expressly relate to an earlier period); and 
 (c) before and after giving effect to this Amendment, no Default or Event of Default shall exist. 
 6.
Guarantor Acknowledgment. Each Guarantor acknowledges and consents to all of the terms and conditions of this Amendment and agrees that this Amendment and all documents executed in connection herewith do not operate to reduce or discharge any
Guarantor’s obligations under the Credit Documents. 
 7. Full Force and Effect. Except as modified hereby, all of the terms and
provisions of the Credit Agreement and the other Credit Documents (including schedules and exhibits thereto) shall remain in full force and effect. 
 8. Expenses. The Borrower agrees to pay all reasonable costs and expenses of the Administrative Agent in connection with the preparation, execution and delivery of this Amendment, including the reasonable fees and expenses of
Moore & Van Allen PLLC. 
 9. Counterparts. This Amendment may be executed in any number of counterparts, each of which when
so executed and delivered shall be deemed an original, and it shall not be necessary in making proof of this Amendment to produce or account for more than one such counterpart. Delivery by any party hereto of an executed counterpart of this
Amendment by facsimile shall be effective as such party’s original executed counterpart. 
 10. Governing Law. This Amendment
shall be governed by, and construed in accordance with, the laws of the State of New York. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  

 13 

 IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of this Amendment to be duly
executed and delivered as of the date first above written. 
  

					
	DOMESTIC BORROWER:	 	MILLIPORE CORPORATION,
		 	a Massachusetts corporation
			
		 	By:	 	 s/ Kathleen B. Allen

		 	Name:	 	Kathleen B. Allen
		 	Title:	 	Vice President and Chief Financial Officer
		
	FOREIGN BORROWERS:	 	MILLIPORE IRELAND B.V.,
		 	a limited liability company existing under the laws of the Netherlands
			
		 	By:	 	 s/ Jeffrey Rudin

		 	Name:	 	Jeffrey Rudin
		 	Title:	 	Managing Director
		
		 	MILLIPORE CORK,
		 	an unlimited company existing under the laws of Ireland
			
		 	By:	 	 s/ Jeffrey Rudin

		 	Name:	 	Jeffrey Rudin
		 	Title:	 	Director
		
		 	MILLIPORE SAS,
		 	a limited liability company existing under the laws of France
			
		 	By:	 	 s/ Kathleen B. Allen

		 	Name:	 	Kathleen B. Allen
		 	Title:	 	By Power of Attorney
		
	FOREIGN GUARANTORS:	 	MILLIPORE INTERNATIONAL HOLDING COMPANY B.V.,
		 	a company existing under the laws of The Netherlands
			
		 	By:	 	 s/ Kathleen B. Allen

		 	Name:	 	Kathleen B. Allen
		 	Title:	 	Director

 MILLIPORE CORPORATION 
 AMENDMENT NO. 1 AND CONSENT 

					
		 	MILLILUX SARL,
		 	a company existing under the laws of Luxembourg
			
		 	By:	 	 s/ Paul O’Connor

		 	Name:	 	Paul O’Connor
		 	Title:	 	Manager
		
		 	MILLIPART SARL,
		 	a company existing under the laws of Luxembourg
			
		 	By:	 	 s/ Paul O’Connor

		 	Name:	 	Paul O’Connor
		 	Title:	 	Manager

 MILLIPORE CORPORATION 
 AMENDMENT NO. 1 AND CONSENT 

					
	ADMINISTRATIVE AGENT:	 	BANK OF AMERICA, N.A., for itself in its capacity as Administrative Agent and on behalf of the Required Lenders
			
		 	By:	 	 s/ Kathleen M. Carry

		 	Name:	 	Kathleen M. Carry
		 	Title:	 	Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00105-of-00352.parquet"}]]